DeNicola L K, Gayle M O, Blake K V
University of Florida Health Science Center, Jacksonville 32207, USA.
Paediatr Drugs. 2001;3(7):509-37. doi: 10.2165/00128072-200103070-00003.
Acute severe paediatric asthma remains a serious and debilitating disease throughout the world. The incidence and mortality from asthma continue to increase. Early, effective and aggressive outpatient therapy is essential in reducing symptoms and preventing life-threatening progression. When complications occur or when the disease progresses to incipient respiratory failure, these children need to be managed in a continuous care facility where aggressive and potentially dangerous interventions can be safely instituted to reverse persistent bronchospasm. The primary drugs for acute severe asthma include oxygen, corticosteroids, salbutamol (albuterol) and anticholinergics. Second-line drugs include heliox, magnesium sulfate, ketamine and inhalational anaesthetics. Future therapies may include furosemide, leukotriene modifiers, antihistamines and phosphodiesterase inhibitors. This review attempts to explore the multitude of medications available with emphasis on pharmacology and pathophysiology.
急性重症小儿哮喘在全球范围内仍然是一种严重且使人衰弱的疾病。哮喘的发病率和死亡率持续上升。早期、有效且积极的门诊治疗对于减轻症状和预防危及生命的病情进展至关重要。当出现并发症或疾病进展至早期呼吸衰竭时,这些儿童需要在持续护理机构中接受治疗,在那里可以安全地采取积极且可能具有危险性的干预措施来逆转持续性支气管痉挛。急性重症哮喘的主要药物包括氧气、皮质类固醇、沙丁胺醇和抗胆碱能药物。二线药物包括氦氧混合气、硫酸镁、氯胺酮和吸入性麻醉剂。未来的治疗方法可能包括呋塞米、白三烯调节剂、抗组胺药和磷酸二酯酶抑制剂。本综述试图探讨众多可用药物,重点关注药理学和病理生理学。